EnviroTech :: Biotech
Lonza Signs Manufacturing Deal with Biopharma Firm
11:55 PM MDT | June 15, 2009 | Deepti Ramesh
Lonza says it has entered into an agreement with biopharmaceutical company Elusys Therapeutics (Pine Brook, NJ) for the production of Anthim, a therapeutic monoclonal antibody in late stage development for the treatment of anthrax infection. Lonza will provide process development services and manufacturing capacity for this product using Lonza’s GS Gene Expression System, under the deal. “Lonza has considerable experience in large-scale manufacturing of monoclonal antibodies and a well-established reputation with regulatory agencies for the production...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee